JPRN-UMIN000009459尚未招募2 期
Phase II/II study of Adriamycin and Cisplatin versus Adriamycin for TC or DC resistant endometrial cancer - Phase II/II study of Adriamycin and Cisplatin versus Adriamycin for TC or DC resistant endometrial cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Obvious infection, serous complication (heart disease, intestinal pneumonia, bleeding) edema greater than grade 2 neuropathy greater that\n grade 2 active other cancer symptomatic brain metastasis pleural effusion or ascites needed treatment pericardiac effusion
研究者
相似试验
已完成
不适用
A Phase II Study of Cisplatin, Pemetrexed and Bevacizumab for Advanced Non-Small Cell (Non squamous cell) Lung CancerAdvanced Non-Small Cell (Non squamous cell) Lung CanceJPRN-UMIN000005763Japanese Foundation for Cancer Research, the Cancer Institute Hospital45
已完成
2 期
A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung CancerAdvanced Non-Small Cell (Non squamous cell)lung CancerJPRN-UMIN000002847Thoracic Medical oncology Thoracic center Cancer Institute Hospital Japanese Foundation for cancer research50
招募中
2 期
A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinomaJPRN-UMIN000051087Kansai Clinical Oncology Group(KCOG)28
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
未知
2 期
Phase 2 study of clarithromycin, pomalidomide and dexamethasone(ClaPD) for patients with relapsed or refractory multiple myelomamultiple myelomaJPRN-UMIN000024166Tokai University34